NEW MJ NEWS

Cara Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022, at 8:30 a.m. ET.

A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has initiated Phase 3 programs for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. The Company has completed the placebo-controlled phase of a Phase 2 proof-of-concept trial of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. A Phase 2 proof-of-concept trial in primary biliary cholangitis patients with moderate-to-severe pruritus is ongoing. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Aurora Cannabis Inc. (ACB) to Host Second Quarter Fiscal Year 2021 Investor Conference Call Thu, January 28, 2021, 7:00 AM

Aurora Cannabis to Host Second Quarter Fiscal Year 2021 Investor Conference Call…

CLS Holdings USA , Inc. (CLSH) Provides Corporate Update and announces Commencement of Trading of its Common Shares on the CSE

CLS Holdings USA, Inc. (OTCQB: CLSH) (CSE: CLSH) Provides Corporate Update and…

 AgraFlora Organics International Inc. (AGRA) (AGFAF) To Develop Terpene-Infused Over-the-Counter CBD Alternative

AgraFlora Organics To Develop Terpene-Infused Over-the-Counter CBD Alternative at New Brunswick Cannabis…

AbbVie Inc. (ABBV) Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio

AbbVie Acquires Syndesi Therapeutics, Strengthening Neuroscience Portfolio AbbVie (NYSE: ABBV) today announced…